Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 4:15:31-38.
doi: 10.2147/BTT.S272063. eCollection 2021.

Convalescent Plasma for the Treatment of Severe COVID-19

Massimo Franchini  1 , Giancarlo Maria Liumbruno  1
Affiliations
Review

Convalescent Plasma for the Treatment of Severe COVID-19

Massimo Franchini et al. Biologics. .

Abstract

The COVID-19 pandemic in 2020 is one of the worst catastrophic events in human history. Several non-specific antiviral drugs have been tried to defeat the SARS-CoV-2, with mixed results. Convalescent plasma from patients who have recovered from COVID-19 is one of the specific biologic therapies being considered to treat SARS-CoV-2 infection. Preliminary studies have shown that convalescent plasma, containing antibodies able to neutralize SARS-CoV-2, is promising in blocking viral replication and improving patients' clinical symptoms. The results of several ongoing randomized controlled trials are, however, keenly awaited to definitively elucidate the safety and efficacy of this blood component in COVID-19. In this narrative review, we summarize the current evidence from the literature on the treatment of severe COVID-19 with convalescent plasma. A concise overview of the hypothesized mechanisms of action is also presented.

Keywords: COVID-19; SARS-CoV-2; convalescent plasma; hyperimmune plasma; therapy.

PubMed Disclaimer

Conflict of interest statement

The authors report no potential conflicts of interest regarding this work.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019;16:69. - PMC - PubMed
    1. Chen Y, Liu Q, Guo D. Coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92:418–423. doi:10.1002/jmv.25681 - DOI - PMC - PubMed
    1. Kuiken T, Fouchier RA, Schutten M, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet. 2003;362(9380):263–270. doi:10.1016/S0140-6736(03)13967-0 - DOI - PMC - PubMed
    1. Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967–1976. doi:10.1056/NEJMoa030747 - DOI - PubMed
    1. de Groot RJ, Baker SC, Baric RS, et al. Commentary: middle east respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol. 2013;87(14):7790–7792. doi:10.1128/JVI.01244-13 - DOI - PMC - PubMed

LinkOut - more resources